Acme United (ACU) Q2 2024 earnings summary

Executive summary

• Net sales for Q2 2024 increased 4% year-over-year to $55.4 million; excluding divested product lines, organic sales grew 8%, driven by market share gains and new product launches.

• Net income for Q2 2024 rose 29% to $4.5 million, with EPS up 14% to $1.09 per diluted share.

• Gross margin improved to 40.8% in Q2 2024 from 37.5% a year ago, attributed to productivity gains.

• Acquisition of Elite First Aid in May 2024 for $6.1 million expanded the first aid and emergency response product portfolio.

• Proceeds from the sale of Camillus and Cuda product lines in November 2023 were used to reduce debt and support growth initiatives.

Financial highlights

• Q2 2024 net sales: $55.4 million (Q2 2023: $53.3 million); six-month sales: $100.4 million (2023: $99.2 million).

• Q2 2024 net income: $4.5 million (Q2 2023: $3.4 million); six-month net income: $6.1 million (2023: $4.4 million).

• Q2 2024 operating income: $6.4 million (Q2 2023: $5.3 million); six-month operating income: $8.9 million (2023: $7.4 million).

• Diluted EPS for Q2 2024: $1.09 (Q2 2023: $0.96); six-month diluted EPS: $1.47 (2023: $1.25).

• Interest expense decreased to $539,000 in Q2 2024 due to lower average debt.

Outlook and guidance

• Management expects continued organic growth and is actively evaluating further acquisitions, leveraging the Elite First Aid acquisition to expand offerings.

• SG&A as a percentage of sales is expected to decline for the full year, with some timing and investment-related fluctuations.

• Gross margin is expected to remain stable, with potential for gradual improvement as higher-margin first aid products grow.

• Management anticipates sufficient liquidity for operations over the next twelve months, supported by cash flow and available credit.

• Seasonal strength anticipated in Q3 due to back-to-school market.